GlassScriptPhysician profile
Christopher John Lafargue
NPI 1306286166
$25,519.26
in general payments reported to CMS, 2019-2025
16 companies · $4,073 in 2025
The $4,073 reported for 2025 was more than what 84% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $304 · 2022: $3,351 · 2023: $9,506 · 2024: $8,287 · 2025: $4,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $1,608 · Education: $31.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,225.00 |
| Food and Beverage | $1,608.16 |
| Education | $31.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $10,986.03 | 2023-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $6,501.63 | 2021-2025 | Enhertu, Lynparza |
| Eisai INC. | $3,735.23 | 2022-2025 | |
| Seagen INC. | $3,071.95 | 2022 | |
| Stryker Corporation | $428.55 | 2021-2022 | |
| Integra Lifesciences Corporation | $197.61 | 2024-2025 | Cusa Clarity, Codman Certas, Codman Hakim |
| Genmab U.S., INC. | $136.48 | 2022-2025 | Tivdak |
| Merck Sharp & Dohme LLC | $110.23 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Myriad Genetic Laboratories, INC. | $105.98 | 2025 | Precisetumor |
| Abbvie INC. | $70.13 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $68.58 | 2022-2024 | |
| Medtronic, INC. | $33.87 | 2024 | Ligasure |
| Daiichi Sankyo INC. | $22.29 | 2025 | Enhertu |
| Astellas Pharma US INC | $18.64 | 2024 | Veozah |
| Fennec Pharmaceuticals, INC. | $16.29 | 2025 | Fyarro |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $15.77 | 2023 | Elahere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lafargue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.